
Yttrium-90 (90Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999–2009)
Keywords: میکروسپرس; Yttrium-90; Radionuclide therapy; DOTATOC; Neuroendocrine tumours; Non-Hodgkin's lymphoma; 90Y-ibritumomab tiuxetan; Microspheres; Radioembolization